| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Paul Stuart Appelbaum | Q7153848 |
| P2093 | author name string | Cassens G | |
| Gutheil TG | |||
| Inglis AK | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuropsychology | Q3872 |
| patient | Q181600 | ||
| schizophrenia | Q41112 | ||
| P304 | page(s) | 477-499 | |
| P577 | publication date | 1990-01-01 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients | |
| P478 | volume | 16 |
| Q51961766 | A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. |
| Q42428654 | A comparative study of cognitive deficits in patients with delusional disorder and paranoid schizophrenia |
| Q37212798 | A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia |
| Q50900954 | Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. |
| Q51697878 | Altered states of consciousness: phenomenology and pharmacology. |
| Q48581092 | Another view of therapy for cognition in schizophrenia |
| Q40445523 | Antipsychotics in older patients. A safety perspective |
| Q44297747 | Atypical antipsychotic drugs improve cognition in schizophrenia |
| Q44773047 | Beyond control of acute exacerbation: enhancing affective and cognitive outcomes. |
| Q37983548 | Can genetics inform the management of cognitive deficits in schizophrenia? |
| Q42470451 | Changes in neuronal activation in patients with bipolar disorder during performance of a working memory task |
| Q46446049 | Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications |
| Q40981929 | Clinical and cognitive diversity of psychotic states arising in late life (late paraphrenia). |
| Q45755673 | Clinical differences between late-onset and early-onset chronically hospitalized elderly schizophrenic patients in Taiwan |
| Q37076307 | Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients |
| Q33729924 | Cognitive deficits and cognitive training in schizophrenic patients: a review |
| Q43813326 | Cognitive dysfunction in schizophrenia. |
| Q35035137 | Cognitive effects and antipsychotic treatment. |
| Q44987733 | Cognitive effects of olanzapine treatment in schizophrenia. |
| Q34604342 | Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis |
| Q40899271 | Cognitive function in schizophrenia--do neuroleptics make a difference? |
| Q74766329 | Cognitive impairment in late life schizophrenia: a suitable case for treatment? |
| Q47643871 | Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia |
| Q48449814 | Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms |
| Q52014550 | Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia. |
| Q38401669 | Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia |
| Q35236187 | Conceptualization of the liability for schizophrenia: clinical implications |
| Q48947559 | Contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first-episode affective disorders |
| Q36534005 | D1and D2and D3 |
| Q99566745 | Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia |
| Q44491995 | Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm |
| Q43819115 | Does cognitive function improve with quetiapine in comparison to haloperidol? |
| Q33888153 | Effect of second-generation antipsychotics on cognition: current issues and future challenges |
| Q44345714 | Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study |
| Q35202584 | Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study |
| Q34201647 | Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study |
| Q43812577 | Effects of risperidone on information processing and attention in first-episode schizophrenia |
| Q35110274 | Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia |
| Q41743497 | Emerging roles for novel antipsychotic medications in the treatment of schizophrenia |
| Q44298145 | Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: One-year followup study |
| Q36228233 | First- and second-generation antipsychotic medication and cognitive processing in schizophrenia |
| Q87917217 | Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study |
| Q44452837 | Glucose effects on cognition in schizophrenia |
| Q24245158 | Haloperidol alone or in combination for acute mania |
| Q24248855 | Haloperidol alone or in combination for acute mania |
| Q73894110 | Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients |
| Q78409616 | Impaired Trail-Making Test-B performance in patients with acute schizophrenia is related to inefficient sequencing of planning and acting |
| Q48179331 | Integration of neuropsychological and behavioral neurological assessment in psychiatry: a case example involving brain injury and polypharmacy |
| Q33877837 | Measuring neuropsychological change in schizophrenia with novel antipsychotic medications |
| Q41194504 | Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy |
| Q34313688 | Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia |
| Q41114744 | Molecular attributes of dopamine receptors: new potential for antipsychotic drug development |
| Q30457807 | Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
| Q38385005 | Neurocognitive functions in euthymic bipolar patients |
| Q40899543 | Neurocognitive impairment in schizophrenia and how it affects treatment options |
| Q44539672 | Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia |
| Q33760630 | Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas |
| Q30988161 | Neuropsychologic functioning and structural MRI of the brain in patients with schizophrenia |
| Q34201654 | Neuropsychological change in schizophrenia after 6 weeks of clozapine |
| Q41652458 | Neuropsychological evidence for frontostriatal dysfunction in schizophrenia |
| Q51000965 | Neuropsychological impairment in first-episode and chronic schizophrenic patients. |
| Q48256833 | Neuropsychological performance of monozygotic twins discordant for bipolar disorder |
| Q51999280 | Normal neurocognitive performance after extended practice in patients with schizophrenia. |
| Q37076346 | Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia |
| Q52194493 | Procedural learning in schizophrenia: evidence from serial reaction time. |
| Q36648517 | Psychomotor slowing in schizophrenia |
| Q34392453 | Quetiapine--efficacy in different domains |
| Q84447079 | Rating scale for the assessment of communication disorders in schizophrenics |
| Q37259258 | Recent advances in treating cognitive impairment in schizophrenia |
| Q48621996 | Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia |
| Q30918894 | Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment |
| Q52182658 | Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. |
| Q33838916 | Switching antipsychotic therapies |
| Q57403374 | The Maudsley early onset schizophrenia study: cognitive function in adolescents with recent onset schizophrenia |
| Q36442322 | The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia |
| Q43601443 | The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia |
| Q51989548 | The effects of increasing resource demand on vigilance performance in adults with schizophrenia or developmental attentional/learning disorders: a preliminary study. |
| Q34139638 | The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review |
| Q45295308 | The nature of learning and memory impairments in schizophrenia |
| Q44026618 | The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone |
| Q40370817 | The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions |
| Q38578857 | The schizophrenia prodrome: promise for prevention |
| Q33605308 | The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. |
| Q36823176 | Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function |
| Q34026104 | Towards the prevention of schizophrenia |
| Q45141205 | Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications |
| Q33877844 | Treating cognitive dysfunction in patients with schizophrenia |
| Q51984253 | Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. |
| Q34322842 | Treatment of the schizophrenia prodrome: is it presently ethical? |
| Q51978430 | Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. |
| Q35187199 | Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms |
| Q37350409 | What do we know about neuropsychological aspects of schizophrenia? |
| Q34640811 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance |
| Q33223628 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia |
| Q33235110 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia |
| Q48951968 | fMRI during affect discrimination in bipolar affective disorder. |
Search more.